Nona Biosciences

Executive Summary

Nona Biosciences is a preclinical-stage biotechnology company pioneering a novel platform for generating fully human heavy chain only antibodies (HCAb/VHH) using its proprietary Harbour Mice® technology. Based in Cambridge, MA, and founded in 2021, the company aims to overcome limitations of conventional antibodies by enabling the discovery of single-domain antibodies that can access challenging epitopes and facilitate the development of next-generation therapeutics such as bispecifics, antibody-drug conjugates (ADCs), and CAR-T therapies. The Harbour Mice platform combines the advantages of fully human sequences with the simplicity and stability of single-domain formats, potentially reducing immunogenicity and streamlining downstream development. While the company is still in early stages and has not disclosed financials or specific pipeline candidates, its platform technology represents a differentiated approach in the competitive antibody engineering space. Nona's success will depend on its ability to validate the platform through partnerships or internal programs, attract funding, and advance toward IND-enabling studies. The therapeutic versatility of HCAb/VHH antibodies positions the company to address multiple high-value targets across oncology and other therapeutic areas.

Upcoming Catalysts (preview)

• TBDAnnouncement of strategic partnership or licensing deal for Harbour Mice platform60% success
• TBDSeries A or larger funding round to advance pipeline50% success
• TBDNomination of lead candidate(s) and initiation of IND-enabling studies30% success